Mark E Dudley
Overview
Explore the profile of Mark E Dudley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
21510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalaitsidou M, Moon O, Sykorova M, Bao L, Qu Y, Sukumaran S, et al.
Front Immunol
. 2023 Nov;
14:1256491.
PMID: 38022678
Transfer of autologous tumor infiltrating lymphocytes (TIL) to patients with refractory melanoma has shown clinical efficacy in a number of trials. However, extending the clinical benefit to patients with other...
2.
Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, et al.
J Immunother Cancer
. 2017 Nov;
5(1):85.
PMID: 29157295
Background: It remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in vivo...
3.
Deniger D, Kwong M, Pasetto A, Dudley M, Wunderlich J, Langhan M, et al.
Clin Cancer Res
. 2017 Jan;
23(2):351-362.
PMID: 28093487
Purpose: This pilot feasibility clinical trial evaluated the coadministration of vemurafenib, a small-molecule antagonist of BRAF mutations, and tumor-infiltrating lymphocytes (TIL) for the treatment of metastatic melanoma. Experimental Design: A...
4.
Goff S, Dudley M, Citrin D, Somerville R, Wunderlich J, Danforth D, et al.
J Clin Oncol
. 2016 May;
34(20):2389-97.
PMID: 27217459
Purpose: Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%)....
5.
Stevanovic S, Draper L, Langhan M, Campbell T, Kwong M, Wunderlich J, et al.
J Clin Oncol
. 2015 Apr;
33(14):1543-50.
PMID: 25823737
Purpose: Metastatic cervical cancer is a prototypical chemotherapy-refractory epithelial malignancy for which better treatments are needed. Adoptive T-cell therapy (ACT) is emerging as a promising cancer treatment, but its study...
6.
Zhang L, Morgan R, Beane J, Zheng Z, Dudley M, Kassim S, et al.
Clin Cancer Res
. 2015 Feb;
21(10):2278-88.
PMID: 25695689
Purpose: Infusion of interleukin-12 (IL12) can mediate antitumor immunity in animal models, yet its systemic administration to patients with cancer results in minimal efficacy and severe toxicity. Here, we evaluated...
7.
Robbins P, Kassim S, Tran T, Crystal J, Morgan R, Feldman S, et al.
Clin Cancer Res
. 2014 Dec;
21(5):1019-27.
PMID: 25538264
Purpose: Although adoptive cell therapy can be highly effective for the treatment of patients with melanoma, the application of this approach to the treatment of other solid tumors has been...
8.
Chandran S, Paria B, Srivastava A, Rothermel L, Stephens D, Dudley M, et al.
Clin Cancer Res
. 2014 Nov;
21(3):534-43.
PMID: 25424856
Purpose: Adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) can mediate durable cancer regression in selected patients with metastatic melanoma. However, the tumor antigens associated with these favorable responses remain...
9.
Kochenderfer J, Dudley M, Kassim S, Somerville R, Carpenter R, Stetler-Stevenson M, et al.
J Clin Oncol
. 2014 Aug;
33(6):540-9.
PMID: 25154820
Purpose: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients...
10.
Lu Y, Yao X, Crystal J, Li Y, El-Gamil M, Gross C, et al.
Clin Cancer Res
. 2014 Jul;
20(13):3401-10.
PMID: 24987109
Purpose: Cancer immunotherapy with adoptive transfer of tumor-infiltrating lymphocytes (TIL) represents an effective treatment for patients with metastatic melanoma, with the objective regressions in up to 72% of patients in...